Shield Therapeutics (STX): Optimism over US deal

Hardman & Co Research
Hardman & Co Research: Shield Therapeutics (STX): Optimism over US deal

18-Sep-2020 / 13:30 GMT/BST


Hardman & Co Research: Optimism over US deal

STX is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru/Accrufer has been approved by the regulators in both Europe and the US. The company has an established commercial relationship with Norgine for Europe and signed a licensing deal with ASK Pharm for the Chinese market in 1H'20. Management has indicated that several discussions are ongoing to secure an optimal commercial deal for the US, which reassured the market. Meanwhile, on current assumptions, STX has a cash runway into 1Q'21.

Please click on the link below for the full report:

https://www.hardmanandco.com/research/corporate-research/optimism-over-us-deal/

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Dr Martin Hall



+44 20 7194 7622

 

mh@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1133733 18-Sep-2020 

fncls.ssp?fn=show_t_gif&application_id=1133733&application_name=news&site_id=financialexpress
UK 100

Latest directors dealings